Core Viewpoint - WuXi AppTec (02268) anticipates significant growth in sales and net profit for the fiscal year ending December 31, 2023, driven by the active development of the antibody-drug conjugate (ADC) industry and the company's unique competitive advantages in securing projects [1][1][1] Financial Performance - The company expects sales revenue to increase by over 100% compared to the same period last year [1] - Net profit is projected to grow by over 80% year-on-year [1] - Adjusted net profit is anticipated to rise by over 100% [1] Industry Developments - The growth is primarily attributed to the ongoing active development within the ADC sector [1] - The company has secured multiple PPQ (Process Performance Qualification) projects since its listing in November 2023 [1] - Collaborations have been established with several innovative biotech companies focused on ADC development [1] Business Outlook - The board expresses strong confidence in the business outlook and remains committed to business development [1] - The company aims to assist clients in developing and advancing various bioconjugate projects [1]
药明合联(02268)发盈喜，预计2023年年度经调整净利润同比增长超过100%